Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AnaptysBio
Biotech
Anaptys plans to split into 2 businesses
AnaptysBio plans to split into two publicly traded companies.
James Waldron
Sep 30, 2025 9:35am
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2
Feb 12, 2025 9:57am
Anaptys scraps atopic dermatitis asset after ph. 2 fail
Dec 11, 2024 11:02am
Anaptys picks up rival to Biogen autoimmune asset from Centessa
Nov 28, 2023 6:30am
Chasing Boehringer, Anaptys hits goal in skin disease phase 3
Oct 9, 2023 9:20am
AnaptysBio's HARP plays dud note, prompting rethink of strategy
Sep 1, 2022 8:05am